BCL-XL overexpression promotes tumor progression-associated properties

[1]  D. Del Bufalo,et al.  Interleukin 8 mediates bcl‐xL‐induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model , 2018, International journal of cancer.

[2]  V. Farini,et al.  miR‐211 and MITF modulation by Bcl‐2 protein in melanoma cells , 2016, Molecular carcinogenesis.

[3]  L. Dassa,et al.  Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL , 2016, Nature Communications.

[4]  M. Hendrix,et al.  Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. , 2016, Pharmacology & therapeutics.

[5]  S. Carradori,et al.  Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells , 2016, Oncotarget.

[6]  Laura H. Tang,et al.  Bcl-xL promotes metastasis independent of its anti-apoptotic activity , 2016, Nature Communications.

[7]  H. Um.  Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species , 2015, Oncotarget.

[8]  Yongping Song,et al.  ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development , 2015, Journal of Hematology & Oncology.

[9]  Baocun Sun,et al.  USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry , 2015, Molecular Cancer Therapeutics.

[10]  M. Hsu,et al.  Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma. , 2015, Cancer research.

[11]  N. Mukherjee,et al.  Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells , 2015, Journal of Investigative Dermatology.

[12]  M. Lamfers,et al.  The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells , 2014, Genes & cancer.

[13]  M. Biffoni,et al.  Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer , 2014, Cell Death and Differentiation.

[14]  A. Letai,et al.  UvA-DARE ( Digital Academic Repository ) Targeting cancer stem cells : Modulating apoptosis and stemness Çolak , 2016 .

[15]  D. Jäger,et al.  Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro , 2013, PloS one.

[16]  Brian J. Smith,et al.  Structure-guided design of a selective BCL-X(L) inhibitor. , 2013, Nature chemical biology.

[17]  Brian E. Schwartz,et al.  CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. , 2012, Cancer research.

[18]  M. Hendrix,et al.  Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications , 2012, Clinical Cancer Research.

[19]  Ming Sun,et al.  Adenovirus-mediated siRNA targeting Bcl-xL inhibits proliferation, reduces invasion and enhances radiosensitivity of human colorectal cancer cells , 2011, World journal of surgical oncology.

[20]  Q. Lan,et al.  Glioma Stem/Progenitor Cells Contribute to Neovascularization via Transdifferentiation , 2011, Stem Cell Reviews and Reports.

[21]  D. Trisciuoglio,et al.  Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells , 2011, Cell Death and Differentiation.

[22]  D. Trisciuoglio,et al.  Bcl-2 Regulates HIF-1α Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90 , 2010, PloS one.

[23]  Sang-Gu Hwang,et al.  Bcl‐XL and STAT3 mediate malignant actions of γ‐irradiation in lung cancer cells , 2010, Cancer science.

[24]  D. Trisciuoglio,et al.  455 Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90 , 2010 .

[25]  Rui Huang,et al.  BCL-xL Is a Target Gene Regulated by Hypoxia-inducible Factor-1α* , 2009, Journal of Biological Chemistry.

[26]  D. Hanahan,et al.  Genetic Ablation of Bcl-x Attenuates Invasiveness without Affecting Apoptosis or Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Cancer , 2009, PloS one.

[27]  D. Trisciuoglio,et al.  Involvement of nuclear factor‐kappa B in bcl‐xL‐induced interleukin 8 expression in glioblastoma , 2008, Journal of neurochemistry.

[28]  H. Immervoll,et al.  Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. , 2007, Neoplasia.

[29]  M. Soengas,et al.  Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells , 2007, Cell Death and Differentiation.

[30]  D. Trisciuoglio,et al.  Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression , 2007, Molecular Cancer Research.

[31]  Baocun Sun,et al.  Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. , 2007, Cancer letters.

[32]  Bing-Hua Jiang,et al.  Cross-talk between Epidermal Growth Factor Receptor and Hypoxia-inducible Factor-1α Signal Pathways Increases Resistance to Apoptosis by Up-regulating Survivin Gene Expression* , 2006, Journal of Biological Chemistry.

[33]  M. Weller,et al.  BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells , 2006, Cell Death and Differentiation.

[34]  Fengqin Gao,et al.  Bcl2 Suppresses DNA Repair by Enhancing c-Myc Transcriptional Activity* , 2006, Journal of Biological Chemistry.

[35]  H. Nakagawa,et al.  Hypoxic microenvironment as a cradle for melanoma development and progression , 2006, Cancer biology & therapy.

[36]  Hong Zhang,et al.  Bcl-xL and bcl-2 proteins in melanoma progression and UVB-induced apoptosis. , 2006, International journal of oncology.

[37]  D. Ribatti,et al.  Bcl‐2 overexpression in melanoma cells increases tumor progression‐associated properties and in vivo tumor growth , 2005, Journal of cellular physiology.

[38]  Shaomeng Wang,et al.  Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. , 2005, Cancer research.

[39]  E. Minet,et al.  Hypoxia-inducible Factor-1-dependent Overexpression of Myeloid Cell Factor-1 Protects Hypoxic Cells against tert-Butyl Hydroperoxide-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[40]  A. Valette,et al.  Localization of Phosphorylated Forms of Bcl-2 in Mitosis : Co-Localization with Ki-67 and Nucleolin in Nuclear Structures and on Mitotic Chromosomes , 2005, Cell cycle.

[41]  A. Valette,et al.  p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. , 2005 .

[42]  G. Taglialatela,et al.  Inhibition of Transcription Factor Activity by Nuclear Compartment-associated Bcl-2* , 2004, Journal of Biological Chemistry.

[43]  G. Daley,et al.  A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth , 2004, Oncogene.

[44]  M. Scarsella,et al.  Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity , 2003, Oncogene.

[45]  G. Semenza,et al.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.

[46]  D. Ribatti,et al.  Bcl-2 Overexpression in Human Melanoma Cells Increases Angiogenesis through Vegf Mrna Stabilization and Hif-1-mediated Transcriptional Activity , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  R. Dummer,et al.  Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. , 2002, The Journal of investigative dermatology.

[48]  G. Zupi,et al.  Bcl‐2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  John Calvin Reed,et al.  Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. , 1997, The American journal of pathology.

[50]  M. Weller,et al.  BCL-2 Family Proteins Modulate Radiosensitivity in Human Malignant Glioma Cells , 2004, Journal of Neuro-Oncology.